Meta-Analysis of the SLCO1B1 c.521T>C Variant Reveals Slight Influence on the Lipid-Lowering Efficacy of Statins
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Several studies have focused on the association between the lipid-lowering efficacy of statins and the SLCO1B1 c.521T>C polymorphism; however, the results are conflicting. The effects of statins show significant variability between individuals. This meta-analysis aimed to investigate the effects of the SLCO1B1 c.521T>C polymorphism on the lipid-lowering effects of statins. Methods: We systematically searched PubMed and Web of Science to screen relevant studies. Meta-analysis was performed to identify the association between SLCO1B1 c.521 polymorphisms and the lipid-lowering effects of statinson the basis of the standard mean difference (SMD) and 95% confidence intervals (CIs). Additionally, we checked for heterogeneity (I2) among studies and evidence of publication bias. We obtained eight studies including 2,012 wild genotype (T/T) and 526 variant genotype (T/C and C/C) cases. Results: No significant difference was observed in the lipid-lowering efficacy of statins between the wildand variant genotypes of SLCO1B1, with a pooled SMD of 0.03 (95% CI: -0.07-0.13). Furthermore, there was no significant effect in the meta-analyses of the variant heterozygote, homozygote, and Chinese populations. Subgroup meta-analysis indicated that the timerequired for the statin to take effectdid notsignificantly affect the association between lipid-lowering efficacy of statins and SLCO1B1 c.521T>C polymorphism. However, thewild genotype improved the lipid-lowering efficacy of simvastatin with a pooled SMD of -0.26 (95% CI: -0.47- -0.05). Conclusions: No significant association was detected between the lipid-lowering efficacy of statins and the SLCO1B1 c.521T>C polymorphism, with the exception of simvastatin.
Abstract
Background: Several studies have focused on the association between the lipid-lowering efficacy of statins and the SLCO1B1 c.521T>C polymorphism; however, the results are conflicting. The effects of statins show significant variability between individuals. This meta-analysis aimed to investigate the effects of the SLCO1B1 c.521T>C polymorphism on the lipid-lowering effects of statins. Methods: We systematically searched PubMed and Web of Science to screen relevant studies. Meta-analysis was performed to identify the association between SLCO1B1 c.521 polymorphisms and the lipid-lowering effects of statinson the basis of the standard mean difference (SMD) and 95% confidence intervals (CIs). Additionally, we checked for heterogeneity (I2) among studies and evidence of publication bias. We obtained eight studies including 2,012 wild genotype (T/T) and 526 variant genotype (T/C and C/C) cases. Results: No significant difference was observed in the lipid-lowering efficacy of statins between the wildand variant genotypes of SLCO1B1, with a pooled SMD of 0.03 (95% CI: -0.07-0.13). Furthermore, there was no significant effect in the meta-analyses of the variant heterozygote, homozygote, and Chinese populations. Subgroup meta-analysis indicated that the timerequired for the statin to take effectdid notsignificantly affect the association between lipid-lowering efficacy of statins and SLCO1B1 c.521T>C polymorphism. However, thewild genotype improved the lipid-lowering efficacy of simvastatin with a pooled SMD of -0.26 (95% CI: -0.47- -0.05). Conclusions: No significant association was detected between the lipid-lowering efficacy of statins and the SLCO1B1 c.521T>C polymorphism, with the exception of simvastatin.
참고문헌 (14)
- Sortica VA, "SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians", Clin Chem Lab Med, 50, pp.441~448 (2012)
- Zhang P, "Effects of statins on rat liver microsomal aspirin esterase activities in vitro", Lat Am JPharm, 32, pp.1501~1507 (2013)
- Igel M, "Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin", Clin Pharmacol Ther, 79, pp.419~426 (2006)
- Hedman M, "Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes", Br J Clin Pharmacol, 61, pp.706~715 (2006)
- Fu Q, "Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals", Eur J Clin Pharmacol, 69, pp.1269~1274 (2013)
- Pasanen MK, "Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin", Clin Pharmacol Ther, 82, pp.726~733 (2007)
- Pasanen MK, "SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid", Pharmacogenet Genomics, 16, pp.873~879 (2006)
- Zhang W, "SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients", Br J Clin Pharmacol, 64, pp.346~352 (2007)
- Tachibana-Iimori R, "Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors", Drug Metab Pharmacokinet, 19, pp.375~380 (2004)
- Yang GP, "Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients", Acta Pharmacol Sin, 31, pp.382~386 (2010)
- Stang A, "Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses", Eur J Epidemiol, 25, pp.603~605 (2010)
- Bailey KM, "Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study", Circ Cardiovasc Genet, 3, pp.276~285 (2010)
- Couvert P, "Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy", Pharmacogenomics, 9, pp.1217~1227 (2008)
- Parmar MK, "Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints", Stat Med, 17, pp.2815~2834 (1998)